---
run_id: halo-evidence-vs-diagnosis-validation-v12-famous-sources-supplied-07
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: famous_sources_supplied
run_number: 7
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 702
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no benefits cases, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: fbda9621700ea5a031af698b8700a95ac925370d84a60c86c1d7bce543e8cc3b
condition_packet_sha256: fbda9621700ea5a031af698b8700a95ac925370d84a60c86c1d7bce543e8cc3b
output_file: model-outputs/famous_sources_supplied-07.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 07)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `famous_sources_supplied`, run 7 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 702, on the frozen condition packet.

## Output

**Recommendation:** Commit to the **Case Evidence Review**.

**Why:**
Your current success is "entangled," meaning your positive commercial signals (expansion bookings, shortened cycles) are likely confounded by temporary pricing bundles and sales narratives rather than product value. The usage data is equally ambiguous: high frequency by managers does not equal utility for the front-line analysts who actually drive the workflow.

The Case Evidence Review is the only proposal that addresses the "Jobs-to-be-Done" (the actual utility of the renewal action plans). By inspecting whether suggestions are accepted, overridden, or impossible to explain, you move from *proxy metrics* (usage percentages and support tags) to *direct evidence* of product-market fit. Scaling now would be premature, and the Adoption Quality Sprint merely tracks behavior without explaining why analysts abandon the tool or why public-sector users cannot justify its output. The Demand Cleanroom tests sales elasticity, but it doesn't tell you how to fix the product if the value proposition is fundamentally flawed.

**The strongest reason against it:**
This approach is slow and qualitative. It ignores the immediate commercial momentum and risks "analysis paralysis" while competitors may move faster. By choosing a retrospective review over the Demand Cleanroom or scaling, you are prioritizing product integrity over short-term revenue optimization and may miss a window to capture expansion dollars while the "halo effect" of the launch is still strong.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" results (should they be run) show that buyers are willing to pay full price for PlanPilot *without* the roadmap pitch or bundle discounts, it would indicate that the perceived value is already high enough to sustain growth despite the current workflow friction. In that case, I would shift the recommendation to "Scale PlanPilot Broadly," as the commercial pull would outweigh the need for immediate workflow refinement.
